Fulcrum Therapeutics Inc FULC
$3.83 $0.02 (0.52%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
FULC Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Fulcrum Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Fulcrum Therapeutics Inc. Stock Analysis FULC
United States Health Care Micro Cap Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2019-07-18. The firm's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). The company uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The firm continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.
Fulcrum Therapeutics Inc (FULC) Chart
Financial Metrics & Statements of Fulcrum Therapeutics Inc (FULC)
FAQ's for Fulcrum Therapeutics Inc (FULC)
- As of August 2026, Fulcrum Therapeutics Inc FULC is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Fulcrum Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Fulcrum Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Fulcrum Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Fulcrum Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Fulcrum Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Fulcrum Therapeutics Inc (FULC)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
